Recruiting Pulmonary Hypertension Studies in Peoria
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis....
Emicizumab in Patients With Acquired Hemophilia A
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquire...
About Pulmonary Hypertension Clinical Trials in Peoria
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 2 pulmonary hypertension clinical trials recruiting participants in Peoria, AZ. These studies are seeking a combined 208 participants. Research is being sponsored by Uniquity One (UNI), University of Washington. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Peoria — FAQ
Are there pulmonary hypertension clinical trials in Peoria?
Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in Peoria, AZ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Peoria?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Peoria research site will contact you about next steps.
Are clinical trials in Peoria free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Peoria studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 2 active trials in Peoria are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov